SCHEMBL3509902

SCHEMBL3509902

Cc1csc(CNC(=O)c2cc(C(N)=O)cc(-c3cccnc3)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.46
NAMPT P43490 1/20 0.43
MKNK1 Q9BUB5 3/20 0.43
MKNK2 Q9HBH9 3/20 0.43
RAB9A P51151 2/20 0.43
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP2E1 P05181 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2A6 P11509 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2B6 P20813 1/20 0.42
WDR5 P61964 1/20 0.42
GRM5 P41594 1/20 0.41
CTPS1 P17812 1/20 0.41
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
NPC1 O15118 1/20 0.40
HSP90AA1 P07900 1/20 0.40
SLC5A7 Q9GZV3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3511082 0.89 RAB9A (0.43) NAMPTRAB9ACYP3A4CYP2C9WDR5
SCHEMBL3686716 0.85 RAB9A (0.48) NAMPTRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3513838 0.84 MAPK1 (0.41) TSHRNAMPTRAB9AWDR5NPC1
SCHEMBL3509630 0.82 ADORA2A (0.46) NAMPTRAB9ANPC1HSP90AA1SLC5A7
SCHEMBL3648778 0.81 MKNK1 (0.42) MKNK1MKNK2RAB9ACYP2E1CYP3A4
SCHEMBL3647405 0.81 ENPP2 (0.52) NAMPTRAB9ASMN1; SMN2GRM5NPC1
SCHEMBL3510035 0.80 RAB9A (0.40) NAMPTRAB9AWDR5NPC1HSP90AA1
SCHEMBL2711113 0.78 NAMPT (0.47) TSHRNAMPTMKNK2RAB9ANPC1
SCHEMBL3646709 0.78 MKNK1 (0.50) MKNK1MKNK2CYP2E1CYP3A4CYP2A6
SCHEMBL3508887 0.78 MAPK1 (0.41) NAMPTRAB9AWDR5NPC1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286145-A1 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY COMENTIS, INC. (US) 2010-11-11 US disclosed
EP-2178837-A2 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY COMENTIS, INC. (US) 2010-04-28 EP disclosed
WO-2009015369-A2 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286145-A1 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY BACE1, BACE2, APP TSHR 4471/4885NAMPT 961/4885MKNK1 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.